[1]王 群,杨 瑾,朱 坤.德国医疗费用控制的经验与启示[J].卫生经济研究,2019,(09):22-24,28.
　WANG Qun,YANG Jin,ZHU Kun.Experience and Enlightenment of German Medical Expenditure Control[J].Journal Press of Health Economics Research,2019,(09):22-24,28.
点击复制

德国医疗费用控制的经验与启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年09期
页码:
22-24,28
栏目:
他山之石
出版日期:
2019-08-23

文章信息/Info

Title:
Experience and Enlightenment of German Medical Expenditure Control
作者:
王 群1; 杨 瑾1; 朱 坤2
1.大连理工大学人文学部公共管理与法学学院,辽宁 大连 116024
2.中国财政科学研究院,北京 100142
Author(s):
WANG Qun; YANG Jin; ZHU Kun
School of Public Administration and Law，Department of Humanities，Dalian University of Technology，Dalian Liaoning 116024，China
关键词:
费用控制; 支付方式改革; 疾病管理
Keywords:
cost control;  payment method reform;  disease management
分类号:
R19
文献标志码:
A
摘要:
德国针对医疗费用不合理上涨，主要采用了医疗保险支付方式改革、实施疾病管理项目以及控制药品费用等一系列控制措施，取得了良好效果，为我国提供以下借鉴：医保部门应主动作为，推进医保支付方式改革；加强预防保健，鼓励医患双方参与慢性病防控；运用法制化手段全面控制药品费用，建立医疗保险药品谈判机制。
Abstract:
In response to the unreasonable rise in medical expenses，Germany has mainly adopted a series of control measures such as reform of medical insurance payment methods， implementation of disease management projects and control of drug costs，and achieved good results. It provides the following reference for China: the medical insurance department should take the initiative to promote medical insurance；promoting the reformation of payment methods； strengthening preventive health care，encouraging both doctors and patients to participate in the prevention and control of chronic diseases； using legal means to comprehensively control drug costs， and establishing a medical insurance drug negotiation mechanism.

参考文献/References:

[1] Busse R, Blümel M, Knieps F, et al. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition[J]. The Lancet, 2017, 390(10097):882-897.
[2] Fraser Institute. Health Care Lessons from Germany, Lessons from Abroad: A Series on Health Care Reform[R]. Vancouver: Fraser Institute, 2013.
[3] OECD. European Observatory on Health Systems and Policies, Germany: Country Health Profile 2017, State of Health in the EU[R]. Paris: OECD, 2017.
[4] Busse R, Blümel M. Germany: Health system review[J]. Health Systems in Transition, 2014, 16(2):1-296.
[5] Klein-Hitpaβ, U, Scheller-Kreinsen, D. Policy trends and reforms in the German DRG-based hospital payment system[J]. Health Policy, 2015, 119(3):252-257.
[6] Walendzik, A. Diagnoses-based risk adjustment in the German remuneration system for outpatient medical care[R]. Duisburg: University of Duisburg-Essen, Institute of Business and Economic Studie, 2011.
[7] WHO Regional Office for Europe. Ambulatory care sensitive conditions in Germany[R]. Copenhagen: WHO Regional Office for Europe, 2015.
[8] WHO Regional Office for Europe. Managing chronic conditions: experience in eight countries[R]. Copenhagen: WHO Regional Office for Europe, 2008.
[9] Health Advances. Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies[EB/OL]. (2018-08-23)[2018-12-29]. https://healthadvancesblog.com/2018/08/23/disease-management-programs-in-germany.
[10] Ullrich W, Marschall U, Graf C. Versorgungsmerkmale des Diabetes mellitus in Disease-Management-Programmen[J]. Diabetes, Stoffwechsel und Herz, 2007, 16(6):407-414.
[11] The Commonwealth Fund. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing[EB/OL]. (2019-01-01)[2019-04-24]. https://doi.org/10.26099/5xrf-wb19.
[12] Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries: Review[J]. Health Systems in Transition, 2016，18(5):1-118.
[13] 中国医疗保险研究会. 医疗保险支付制度改革政策研究报告[R]. 北京: 中国医疗保险研究会, 2015.
[14] 杨辉. 初级卫生保健与中国全科医学的发展及挑战[J]. 中国全科医学, 2018, 21(28):3407-3410.

相似文献/References:

[1]贾洪波,段文琦.基本医保按病种分值付费的实践探讨[J].卫生经济研究,2018,(05):57.
[2]朱 坤.县级公立医院按病种付费实施现状与建议 ——基于项目省的实践[J].卫生经济研究,2019,(03):5.
　ZHU Kun.Current Status and Recommendations for County-level Public Hospitals to Pay for Diseases——Based on the Practice of the Project Province[J].Journal Press of Health Economics Research,2019,(09):5.
[3]颜维华,谭华伟,张培林,等.日本诊断群分类支付制度改革经验及启示[J].卫生经济研究,2019,(03):39.
　YAN Wei-hua,TAN Hua-wei,ZHANG Pei-lin,et al.Japanese Diagnostic Group Classification Payment System Reform Experience and Enlightenment[J].Journal Press of Health Economics Research,2019,(09):39.
[4]李乐乐,俞 乔.云南省玉溪市DRGs付费改革的实践探索[J].卫生经济研究,2019,(03):47.
　LI Le-le,YU Qiao.Practice Exploration of DRGs Payment Reform in Yuxi City，Yunnan Province[J].Journal Press of Health Economics Research,2019,(09):47.
[5]陈诚诚,郭佳琪.长期护理费用控制与支付方式研究——以S市长期医疗护理保险试点为例[J].卫生经济研究,2020,(02):49.
　CHEN Cheng-cheng,GUO Jia-qi.Study on the Control and Payment Methods of Long-term Care Costs——Taking Long-term Medical Care Insurance Pilot in S City as An Example[J].Journal Press of Health Economics Research,2020,(09):49.
[6]石连忠,梅 彦,余 震,等.杭州市DRG中医支付政策的实践探索[J].卫生经济研究,2021,38(12):16.
　SHI Lian-zhong,MEI Yan,YU Zhen,et al.Practical Exploration of DRG Payment Policy for Traditional Chinese Medicine in Hangzhou[J].Journal Press of Health Economics Research,2021,38(09):16.
[7]李秀梅,刘 理,胡海源,等.DRG支付下脑卒中患者住院费用控制研究[J].卫生经济研究,2022,39(1):44.
　LI Xiu-mei,LIU Li,HU Hai-yuan,et al.Research on the Control of Hospitalization Expenses of Stroke Patients in the Context of DRG Payment[J].Journal Press of Health Economics Research,2022,39(09):44.
[8]陈奕男.长期护理保险费用控制的机理、类型与策略[J].卫生经济研究,2022,39(2):45.
　CHEN Yi-nan.The Mechanism, Type and Strategy of Long-Term Care Insurance Cost Control[J].Journal Press of Health Economics Research,2022,39(09):45.
[9]赵 宁,高广颖,吴妮娜,等.门诊按人头付费方式改革的实践探索[J].卫生经济研究,2023,40(1):29.
　ZHAO Ning,GAO Guangying,WU Nina,et al.Practice of Reform for Outpatient Payment by Capitation[J].Journal Press of Health Economics Research,2023,40(09):29.
[10]杨 菁,李梦滢,沈际勇.中医优势病种支付方式改革试点经验与启示[J].卫生经济研究,2023,40(12):33.
　YANG Jing,LI Mengying,SHEN Jiyong.Experience and Enlightenment of the Pilot Reform of Payment Methods for Dominant Diseases of Traditional Chinese Medicine[J].Journal Press of Health Economics Research,2023,40(09):33.

更新日期/Last Update: 2019-08-23